SecBot SecBot
6-KF-1/APRESS-RELEASE ·Filed Nov 9, 2026

EVAX

Evaxion A/S
NEUTRAL
Impact 3/10
Horizonweeks Processed7d 18h ago SEC0001171843-26-007255
Actionable Insight • Neutral

Monitor SEC effectiveness of the F-1 registration statement, which would allow EIB to begin selling shares. Watch for any EIB sales that could create overhang on EVAX stock given the 38.45 million ordinary shares registered (8.5% of current outstanding). The company's cash burn rate and need for additional capital remain key concerns.

DirectionNeutral
Confidencehigh
Horizonweeks

How the stock moved after the report

NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+5
Entry
$2.75
T+0 close · Nov 9, 2026 · via day close
Latest settled
+0.73%
T+5 · $2.77
Vs SPY
+2.42%
α at T+5
Next horizon
T+20
in 21d
  1. T+0 · Nov 9 $2.75entry
  2. T+1 · 7d ago +4.00%α +4.37% · $2.86
  3. T+5 · 20h ago +0.73%α +2.42% · $2.77
  4. T+20 · in 21d Pending
  5. T+60 · in 3mo Pending
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Evaxion filed Amendment No. 1 to its F-1 registration statement and a related 6-K press release on November 9, 2026, to register for resale up to 38,450,000 ordinary shares (769,000 ADSs) issuable upon exercise of warrants held by the European Investment Bank (EIB) under a July 2025 debt settlement agreement. The company is not selling securities or receiving proceeds from the resale; it received a EUR 3.5 million debt cancellation in exchange for the warrants and may receive up to approximately $1.5 million if the warrants are exercised. The filing is a routine procedural step to fulfill registration rights granted to EIB, not a new capital raise.

Key Financial Metrics

Rev Growth
+125.1%

Key Facts

  • Evaxion filed Amendment No. 1 to Form F-1 (File No. 333-291685) on November 9, 2026, registering up to 38,450,000 ordinary shares (769,000 ADSs) for resale by EIB.
  • The shares are issuable upon exercise of warrants issued to EIB under a July 11, 2025 debt settlement agreement, which cancelled EUR 3.5 million of a EUR 7 million loan.
  • Evaxion is not selling any securities and will not receive proceeds from the resale; it may receive up to DKK 9,612,500 (approx. $1.5 million) if warrants are exercised.
  • The warrants have an exercise price of DKK 0.25 per ordinary share, expire in ten years, and were issued at an effective conversion price of $4.87 per ADS (89% premium to market at the time).
  • As of September 30, 2026, Evaxion had 451,074,156 ordinary shares outstanding; full warrant exercise would bring total to 489,524,156 ordinary shares.
  • The registration statement has not yet become effective; no sales can occur until it is declared effective by the SEC.
  • Evaxion's cash and cash equivalents were $14.0 million as of June 30, 2026, down from $23.2 million at December 31, 2025.
  • The company reported revenue of $7.5 million in FY2025 (up from $3.3 million in FY2024) and a net loss of $7.7 million.

Financial Impact

EUR 3.5 million debt cancellation already received; potential additional gross proceeds of up to DKK 9,612,500 (approx. $1.5 million) from warrant exercise. No new capital raised.

debtequitydilution

Risk Factors

  • Potential overhang from EIB resale of up to 38.45 million ordinary shares (769,000 ADSs) once registration becomes effective.
  • Company's cash position declining ($14.0M at June 30, 2026 vs. $23.2M at Dec 31, 2025) with ongoing operating losses.
  • Registration statement not yet effective; timing of effectiveness uncertain.
  • Warrant exercise is uncertain and contingent on EIB's decision; company may receive no additional proceeds.

Market Snapshot

Exchange
Nasdaq
Sector
Biological Products, (No Diagnostic Substances)
Analyst Consensus
90% bullish (10 analysts)

Investment Themes

Documents Analyzed

This report is based on 11 SEC documents filed with EDGAR.

DocumentAccession Number
6-K Filing (EVAX), Batch item 10001171843-26-007255
Exhibit: exh_991.htm0001171843-26-007254
Document: 0001171843-26-007255-index-headers.htmlpress-3398322
Document: 0001171843-26-007255-index.html0001171843-26-007255
Document: 0001171843-26-007255.txt0001171843-26-007255
F-1/A Filing (EVAX), Batch item 60001171843-26-007254
Exhibit: exh_231.htm0001171843-26-007255
Document: 0001171843-26-007254-index-headers.html0001171843-26-007255
Document: 0001171843-26-007254-index.html0001171843-26-007255
Document: 0001171843-26-007254.txt0001171843-26-007255
PRESS-RELEASE Data (Synthetic)0001171843-26-007255

Track record

50 reports on EVAX

Performance horizon

7 of 11 bullish or bearish reports moved the stock their way by T+1. Best: +22.94% at T+5 after the Mar 5, 2026 report. 10 of 11 went positive at some point.

Filters
  1. Nov 12, 20264d ago 6-K Neutral 2/10 Entry $2.77 to $2.74 Now $2.77 −0.00% ▼ −1.08% −0.72% vs SPY
  2. Nov 12, 20264d ago Press Release Neutral 1/10 Entry $2.77 to $2.74 Now $2.77 −0.00% ▼ −1.08% −0.72% vs SPY
  3. Nov 9, 20267d ago 6-K / F-1/A / PRESS-RELEASE Neutral 3/10 Viewing Entry $2.75 to $2.86 Now $2.77 +0.73% ▲ +4.00% +4.37% vs SPY
  4. Nov 6, 202610d ago 6-K Neutral 4/10 Entry $3.00 to $2.75 Now $2.77 −7.67% ▼ −8.33% −10.70% vs SPY
  5. Nov 6, 202610d ago Press Release Neutral 4/10 Entry $3.00 to $2.75 Now $2.77 −7.67% ▼ −8.33% −10.70% vs SPY
  6. Nov 4, 202612d ago 6-K Neutral 3/10 Entry $2.97 to $2.76 Now $2.77 −6.73% ▼ −7.07% −2.66% vs SPY
  7. Nov 4, 202612d ago 6-K Neutral 3/10 Entry $2.97 to $2.76 Now $2.77 −6.73% ▼ −7.07% −2.66% vs SPY
  8. Nov 3, 202613d ago 6-K Neutral 4/10 Entry $2.96 to $2.97 Now $2.77 −6.42% ▲ +0.34% −1.31% vs SPY
  9. Oct 30, 202617d ago 6-K Neutral 2/10 Entry $2.93 to $2.92 Now $2.77 −5.46% ▼ −0.34% +0.14% vs SPY
  10. Oct 30, 202617d ago Press Release Neutral 3/10 Entry $2.93 to $2.92 Now $2.77 −5.46% ▼ −0.34% +0.14% vs SPY
Showing 10 of 50

US Market Status

Market Closed · Opens in 6h 33m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Nov 9, 2026